Market Place
Sourcing Support
Corbus Pharma Reaches Milestone In CRB-913 Obesity Treatment
14 Apr 2026 //
GLOBENEWSWIRE
Corbus Pharma Aligns With FDA On CRB-701 Registration For HNSCC
07 Apr 2026 //
GLOBENEWSWIRE
Corbus Pharma To Present Phase 1A Results Of Oral CRB-913
10 Dec 2025 //
GLOBENEWSWIRE
Corbus Pharma Updates On Q3 2025 Finances & Corporate Progress
12 Nov 2025 //
GLOBENEWSWIRE
Corbus Shows CRB-701 Strong Results In HNSCC & Cervical Cancer
18 Oct 2025 //
GLOBENEWSWIRE
Corbus Pharma To Unveil CRB-701 Ph1/2 Results At ESMO 2025
14 Oct 2025 //
GLOBENEWSWIRE
FDA Grants Fast Track To Corbus Nectin-4 ADC CRB-701 In HNSCC
16 Sep 2025 //
GLOBENEWSWIRE
Corbus to Present CRB-701 Ph 1/2 Data at ESMO 2025
30 Jul 2025 //
GLOBENEWSWIRE
Corbus Doses First Patient in CRB-701 + Pembrolizumab Trial
25 Jun 2025 //
GLOBENEWSWIRE
Corbus Pharmaceuticals at Investor Conferences
25 Feb 2025 //
GLOBENEWSWIRE
CRB-701 Shows Safety, Efficacy In Ph1 Nectin-4 ADC Study At ASCO-GU
14 Feb 2025 //
GLOBENEWSWIRE
Corbus Pharma Announces Clinical Data for CRB-701
11 Feb 2025 //
GLOBENEWSWIRE
Corbus Pharma to Present at Guggenheim SMID Cap Biotech Conference
28 Jan 2025 //
GLOBENEWSWIRE
Corbus To Present CRB-701 Dose Study Data At ASCO GU 2025
08 Jan 2025 //
GLOBENEWSWIRE
Corbus Doses First Patient in CRB-601 Solid Tumor Study
09 Dec 2024 //
GLOBENEWSWIRE
FDA Grants Fast Track Designation to CRB-701 for Cervical Cancer
03 Dec 2024 //
GLOBENEWSWIRE
Corbus Completes Enrollment Of CRB-701 Phase 1 Trial
16 Oct 2024 //
GLOBENEWSWIRE
Corbus To Present At Cantor Global Health Conference
05 Sep 2024 //
GLOBENEWSWIRE
SYS6002 Nectin-4 ADC Shows Safety, Efficacy In Positive Tumor Patients
01 Jun 2024 //
GLOBENEWSWIRE
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial
02 Apr 2024 //
GLOBENEWSWIRE
CRB-701 Demonstrates Efficacy in Patients with Nectin-4 Positive Tumors
26 Jan 2024 //
GLOBENEWSWIRE
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
23 Jan 2024 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on CRB-601
02 Nov 2023 //
GLOBENEWSWIRE
Corbus Presents the Characterization of its Next Generation Nectin-4 ADC CRB-701
16 Oct 2023 //
GLOBENEWSWIRE
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its CRB-601
27 Sep 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701
19 Sep 2023 //
PR NEWSWIRE
Corbus to Present Latest Pre-Clinical Data on CRB-601 av?8 Blocking Antibody
01 May 2023 //
PR NEWSWIRE
Corbus Hosting Virtual `Meet the Expert` Series: Blocking TGF? with CRB-601
18 Apr 2023 //
PR NEWSWIRE
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601
17 Apr 2023 //
PR NEWSWIRE
Corbus Pharma Data on CRB-601 av?8 Blocking Antibody Accepted for Presentation
14 Mar 2023 //
PR NEWSWIRE
Corbus expands oncology pipeline with the addition of Nectin-4 targeting ADC
13 Feb 2023 //
PR NEWSWIRE
Tiny Corbus pays $7.5M for rival to Seagen`s oncology ADC Padcev
13 Feb 2023 //
FIERCE BIOTECH
Corbus Presents Latest Preclinical Data for CRB-601 at SITC
10 Feb 2023 //
PRESS RELEASE
